

ENDONOVO THERAPEUTICS, INC.  
6320 Canoga Avenue, 15th Floor, Woodland Hills, CA 91367  
INFORMATION STATEMENT

WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY

THIS IS NOT A NOTICE OF A MEETING OF STOCKHOLDERS AND NO STOCKHOLDERS' MEETING WILL BE HELD TO CONSIDER ANY MATTER DESCRIBED HEREIN. THIS INFORMATION STATEMENT IS BEING FURNISHED TO YOU SOLELY FOR THE PURPOSE OF INFORMING YOU OF THE MATTERS DESCRIBED HEREIN.

Information Concerning the Actions by Written Consent This Information Statement is being furnished to the stockholders of Endonovo Therapeutics, Inc., a Delaware corporation (the "Company", "we", "us" or "our"), pursuant to applicable Delaware law for the purpose of informing our stockholders that, on December 3, 2025, our board of directors approved by written consent, and the stockholders holding a majority of the voting power of the Company, also approved by written consent, an amendment of the Articles of Incorporation of the Company to implement a recapitalization of the issued and outstanding shares of Common Stock. The recapitalization will involve a reverse stock split on a 1- for-1000 basis, whereby shareholders will receive one share of Common Stock for every 1000 shares currently held. Our intention is that the reverse split is to be affected no later than January 31, 2026, but required regulatory approvals may delay this event. Fractional shares will not be issued in connection with the reverse split; any fractional shares will be rounded down to the nearest whole share. Under the laws of the State of Delaware and our bylaws, stockholder action may be taken by written consent without a meeting of the stockholders. The written consent of our board of directors and the written consent of the stockholders holding a majority of the voting power of the Company are sufficient to approve the amendment described above (the "Amendment"). Therefore, no proxies or consents were or are being solicited in connection with the Amendment. After the expiration of the twenty (20) day period required under Rule 14c-2 promulgated under the Exchange Act, and in accordance with the laws of the State of Delaware, and after FINRA approval of the action, we intend to file a Certificate of Amendment to our Articles of Incorporation to affect the Amendment. The proposed Certificate of Amendment, will become effective when it has been accepted for filing by the Secretary of State of the State of Delaware. Such filing will occur at least twenty (20) days after this information statement is filed with the Securities and Exchange Commission (the "SEC") and first sent or given to our stockholders.

**Record Date.** Our board of directors has fixed the close of business on December 3, 2025 (the "Record Date"), as the record date for determining our stockholders who are entitled to receive this Information Statement. Only our stockholders of record as of the Record Date are entitled to notice of the information disclosed in this Information Statement. As of the Record Date, there were 1,807,556,313 shares of our Common Stock issued and outstanding. Stockholders as of the Record Date who did not consent to the Amendment are not entitled to dissenters' rights or appraisal rights in connection with the Amendment under the laws of the State of Delaware or under our bylaws.

**Expenses.** The cost of preparing and furnishing this Information Statement will be borne by us. We may request brokerage houses, nominees, custodians, fiduciaries and other like parties to forward this Information Statement to the beneficial owners of our Common Stock held on the Record Date.

**Stockholders Sharing an Address** We will deliver, or cause to be delivered, only one copy of this Information Statement to multiple stockholders sharing an address unless we have received contrary instructions from one or more of the stockholders. We undertake to promptly deliver, or cause to be promptly delivered, upon written or oral request, a separate copy of this Information Statement to a stockholder at a shared address to which a single copy of this Information Statement is delivered. A stockholder can notify us that the stockholder wishes to receive a separate copy of this Information Statement by contacting us at the address or phone number set forth above. Conversely, if multiple stockholders sharing an address receive multiple Information Statements and wish to receive only one, such stockholders can notify us at the address or phone number set forth above. Additional Information Regarding the Amendment

#### *Overview*

The Amendment will have the effect of a reverse stock split on a 1- for-1000 basis, whereby shareholders will receive one share of Common Stock for every 1000 shares currently held. The reverse split is to be affected no later than January 31, 2026. Fractional shares will not be issued in connection with the reverse split; any fractional shares will be rounded down to the nearest whole share.

**Following the reverse stock split, 1,807,556,313 issued and outstanding shares of Common Stock will be reduced to approximately 1,807,557 shares, subject to adjustments for rounding and not reversing below 1 share per shareholder.**

#### **Reasons for the reverse stock split:**

Management believes that the reverse stock split is in the best interest of the Company for several reasons:

1. **Improved Market Perception:** By reducing the total number of outstanding shares, the reverse split aims to alleviate the perceived depressive effect that a large number of shares may have on the public market price of our common stock.

2. **Enhanced Financial Flexibility:** The reverse split will make a significant number of authorized but unissued shares of common stock available. This increased flexibility will allow the Company to efficiently:
  - Structure potential future financing,
  - Capitalize on business opportunities, such as acquisitions, and
  - Address other corporate needs as they arise, all without the time and expense of convening a shareholder meeting to authorize additional shares.
3. **Positioning for Uplisting:** One of the Company's strategic goals is to have its securities listed on NASDAQ or another national stock exchange. A higher stock price is often a prerequisite for such listings. By reducing the number of outstanding shares, the reverse split is expected to have the effect of increasing the market price of the Company's common stock, thereby improving the Company's eligibility for listing on a national exchange.

Management believes these benefits will collectively strengthen the Company's financial position, enhance shareholder value, and support the Company's long-term strategic objectives.

### **Effect of the reverse stock split**

The reverse stock split will not alter the rights of existing stockholders, nor will it result in the elimination of any stockholder. Fractional shares will not be issued; instead, any fractional shares will be rounded down to the nearest whole share, with no stockholder holding fewer than one share.

However, stockholders with fewer than 100 shares of common stock may experience higher commission costs relative to the value of their shares when selling, potentially resulting in transaction costs exceeding the value of the shares sold.

The reverse stock split is not being undertaken as part of any anti-takeover strategy. The decrease in authorized shares of common stock did not arise from any knowledge of specific efforts to accumulate the Company's securities or to gain control through a merger, tender offer, proxy solicitation, or similar actions. Furthermore, this action was not intended to frustrate any such efforts or to prevent another party from acquiring a controlling interest or seeking representation on the Board of Directors.

The issuance of additional shares of common stock following the reverse split could dilute earnings per share as well as the equity and voting power of existing stockholders. Such issuance may also adversely impact the market price of our common stock. However, if additional shares are issued in connection with favorable business opportunities, such transactions could enhance the market price of our stock.

### *Stockholder Rights*

**Voting Rights:** Each share of common stock entitles the holder to one vote on all matters submitted to a vote of stockholders.

**Dividends:** Holders of common stock are entitled to receive dividends, if and when declared by the Board of Directors, out of funds legally available for distribution. To date, the Company has not declared or paid dividends and currently anticipates retaining all earnings, if any, to support the development and growth of the business. Future dividend declarations will be determined at the discretion of the Board, considering factors such as earnings, financial condition, capital requirements, and other relevant considerations.

Each share of Series AA Preferred votes with the Common Stock and has 100,000 votes. Accordingly, Mr. Collier has an additional 2,500,000,000 votes in addition to his 45,026,212 common shares and together has an aggregate of 2,545,026,212 shares equaling 59.08% of the voting power in the Company.

### **Additional Information About the Company**

We file annual, quarterly and other reports with the OTCMarkets The Company's filings are available to the public at [www.otcmartkets.com](http://www.otcmartkets.com)at [www.otcmartkets.com](http://www.otcmartkets.com) You may also request a copy of the Company's filings with the OTCMarkets, at no cost, by writing to us at 6320 Canoga Avenue, 15<sup>th</sup> Floor, Woodland Hills, CA 91367 or by contacting us by phone at (877) 796-1456

**WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY**

By Order of the Board of Directors:

Date: December 3, 2025

By: /s/ Alan Collier

Alan Collier  
CEO